Want to see HK:0911 full AI Analyst Report?
Top Page
Qianhai Health Holdings Ltd.
(0911)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$0.39
▲(37.50% Upside)
Action:Reiterated
Date:09/22/26
The score is driven primarily by improved financial performance and low balance-sheet risk (turnaround to positive earnings and stronger cash flow, with minimal leverage). However, the overall rating is held back by very weak technical momentum (below major moving averages with negative MACD and oversold indicators) and only moderate valuation support (P/E ~15 with no dividend yield data).
Positive Factors
Return to profitability
The return to positive net income and operating profit shows a meaningful improvement from the large losses recorded in 2022–2023. If maintained, restored profitability can support internal funding, reduce dependence on external capital, and provide a more stable base for operations over the next several quarters.
Negative Factors
Very thin margins
Very thin gross and net margins leave little room to absorb pricing pressure, cost increases, or execution setbacks. Although profitability has returned, the narrow earnings cushion means modest operational deterioration could materially reduce profits and make the turnaround difficult to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to profitability
The return to positive net income and operating profit shows a meaningful improvement from the large losses recorded in 2022–2023. If maintained, restored profitability can support internal funding, reduce dependence on external capital, and provide a more stable base for operations over the next several quarters.
Read all positive factors
Qianhai Health Holdings Ltd. (0911) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$66.93M
Dividend Yield121.95%
Average Volume (3M)54.54K
Price to Earnings (P/E)15.2
Beta (1Y)-0.42
Revenue Growth-18.16%
EPS GrowthN/A
CountryHK
Employees19
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding169,445,000
10 Day Avg. Volume13,162
30 Day Avg. Volume54,538
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.12
Price to Sales (P/S)0.07
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Qianhai Health Holdings Ltd. Business Overview & Revenue Model
Company Description
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health...
Qianhai Health Holdings Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
84
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 453.03M | 677.12M | 519.70M | 961.29M | 1.96B | 283.40M |
| Gross Profit | 15.82M | 22.26M | 29.67M | -35.60M | 76.48M | 16.04M |
| EBITDA | 5.29M | 7.19M | 16.32M | -50.23M | -231.24M | 2.06M |
| Net Income | 4.01M | 5.94M | 1.31M | -52.70M | -233.70M | -888.00K |
Balance Sheet | ||||||
| Total Assets | 441.43M | 408.39M | 407.31M | 478.12M | 534.43M | 738.63M |
| Cash, Cash Equivalents and Short-Term Investments | 17.88M | 61.38M | 23.51M | 19.52M | 1.64M | 2.47M |
| Total Debt | 107.00K | 424.00K | 1.03M | 487.00K | 1.19M | 7.83M |
| Total Liabilities | 47.39M | 17.19M | 21.74M | 94.00M | 97.73M | 68.09M |
| Stockholders Equity | 394.05M | 391.20M | 385.57M | 384.11M | 436.70M | 670.53M |
Cash Flow | ||||||
| Free Cash Flow | 34.53M | 38.78M | 4.19M | 857.00K | -5.26M | -44.19M |
| Operating Cash Flow | 34.54M | 38.80M | 4.20M | 857.00K | -5.26M | -44.18M |
| Investing Cash Flow | -3.00K | -14.00K | 246.00K | 17.77M | 12.34M | 46.84M |
| Financing Cash Flow | -324.00K | -648.00K | -712.00K | -743.00K | -7.91M | -16.56M |
Qianhai Health Holdings Ltd. Technical Analysis
Negative
0.28
Price Trends
0.48
Negative
0.59
Negative
0.48
Negative
Market Momentum
-0.03
Negative
30.61
Neutral
43.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.48, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 30.61 is Neutral, neither overbought nor oversold. The STOCH value of 43.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0911.
Qianhai Health Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.85B | 6.46 | 13.26% | 9.28% | -0.47% | -0.40% | |
61 Neutral | HK$66.93M | 15.19 | 1.02% | 121.95% | -18.16% | ― | |
54 Neutral | HK$223.30M | -0.21 | -154.56% | ― | -7.12% | -523.61% | |
53 Neutral | HK$423.47M | 105.56 | 0.34% | 84.69% | -8.30% | -44.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$260.16M | -6.90 | -8.05% | 2.26% | 12.89% | -2.56% | |
43 Neutral | HK$131.06M | -4.31 | -21.73% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:0911
Qianhai Health Holdings Ltd.
0.36
0.08
28.57%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
-0.03
-27.27%
HK:0455
Tianda Pharmaceuticals Ltd.
0.12
-0.03
-18.24%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.38
-0.06
-13.64%
HK:1498
PuraPharm Corp. Ltd.
0.25
-0.19
-43.02%
HK:2633
Jacobson Pharma Corporation Limited
0.98
-0.40
-29.19%
Qianhai Health Holdings Ltd. Corporate Events
Qianhai Health Shifts Hong Kong Principal Office to Causeway Bay
Sep 18, 2026
Qianhai Health Holdings Limited has announced a change to its principal place of business in Hong Kong, which will move to Room 1622, 16/F, Leighton Centre, 77 Leighton Road, Causeway Bay, effective 22 September 2026. The company emphasized that i...
Qianhai Health’s Interim Profit Holds Up Despite Sharp Revenue Drop
Aug 12, 2026
Qianhai Health Holdings reported unaudited interim revenue of HK$116.76 million for the six months ended 30 June 2026, down sharply from HK$340.85 million a year earlier, with gross profit falling to HK$7.71 million from HK$14.16 million as cost o...
Qianhai Health Sets August Board Meeting for Interim Results and Dividend
Jul 29, 2026
Qianhai Health Holdings Limited has scheduled a board meeting for 12 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The board will also consider the publication of these results and whether t...
Qianhai Health Warns of Sharp Profit Drop on Semiconductor Supply Bottlenecks
Jul 24, 2026
Qianhai Health Holdings has warned that profit attributable to its owners for the six months ended 30 June 2026 is expected to fall by about 35% to 45% from a year earlier. The company said the decline stems from lower revenue and gross profit, ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.